The scientific community has been alarmed by the possible immunological evasion, higher
infectivity, and severity of disease caused by the newest variants of SARS-CoV-2. The spike …

The structure and post-translational processing of the SARS-CoV-2 spike glycoprotein (S) is
intimately associated with the function of the virus and of sterilising vaccines. The surface of …

Controlling the global COVID-19 pandemic depends, among other measures, on developing
preventive vaccines at an unprecedented pace. Vaccines approved for use and those in …

Spike (S) protein is the primary antigenic target for neutralization and vaccine development
for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It decorates the …

The trimeric spike (S) glycoprotein, which protrudes from the SARS-CoV-2 viral envelope,
binds to human ACE2, initiated by at least one protomer's receptor binding domain (RBD) …

Authorized vaccines against SARS-CoV-2 remain less available in low-and middle-income
countries due to insufficient supply, high costs, and storage requirements. Global immunity …

Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Effective and safe vaccines are invaluable tools in the arsenal to fight infectious diseases.
The rapid spreading of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r-receptor binding domain (RBD) protein vaccines. Methods A …

Multivalent display of SARS-CoV-2 RBDs (receptor-binding domains, prime proteins for viral
infection and as vaccine immunogens) affects infectivity and as immunogens on a virus-like …